We have obtained insurance coverage for our clinical trials in accordance with market standards and in compliance with applicable Israeli law. However, our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for Aramchol, or any other product candidate, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.

Maybe acute mitochondrial failure as in mitochondria paper you posted about 3 months ago. Remember big holes mitochondrial membrane.

Maria Blasco has a PHD in molecular biology and is the director of The Cancer Research Center in Spain. It was primarily reading her work that convinced me to take TA 65for 3 years, and now a group of other telomerase activators. My real concern was that it may convert an insolent cancer into a more aggressive form, but she put those fears to rest. I’m never certain why Elizabeth Blackburn and others just sort of ignore her findings. She’s totally legit.

        We maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.

“Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician’s Expectation Be Matched by the Reality?”

I find your idea that can decease inflammation by increase of subcutaneous adipose tissue a very novel idea. Furthermore, since in humans, excess fat is generally stored as as midline abdominal fat, doesn’t seem any way to increase subcutaneous fat beyond normal physiologic amount, without increasing abdominal fat. In short, you seem to be proposing something which as far as I know, is impossible.

We are seeking to expand our clinical operations for Aramchol to multiple other indications in order to expand our pipeline, commercial potential and ultimately de-risk the Company for the success of any one given trial. If we initiate additional clinical trials, this may divert a significant amount of Company resources and may be unsuccessful.

I’m grateful to Dr Paul Rivas whose comment in this blog led me to read a little about it.  Inositol hexaphosphate (IP6) is a bio-available form of Inositol, which is in the B-vitamin family.  It has a major benefit for certain kinds of anxiety and depression, and minor benefits for blood sugar, insulin sensitivity, and cancer prevention.

Visual inspection of funnel plot asymmetry suggested potential publication bias for the effects of statin therapy on plasma ADMA concentrations (Supplementary Figure S2). Imputation of theoretically missed studies using Duval and Tweedie’s trim-and-fill method added 3 studies, leading to an imputed WMD of − 0.100 (95%CI: − 0.127 to − 0.074) which was still significant (Supplementary Figure S2). The “fail safe N” test showed that 50 theoretically missing studies would be needed to add to the analysis of the effect of statin therapy on plasma ADMA concentrations in order to yield a statistically non − significant overall effect. Likewise, Begg’s rank correlation test (Kendall’s Tau with continuity correction = − 0.167, Z = 0.626, two-tailed p = 0.532) and Egger’s linear regression tests suggested no evidence of publication bias (intercept = − 0.478, 95%CI = − 1.150 to 0.195, t = 1.679, df = 7.00, two-tailed p = 0.137).

Due to Western sanctions over the Russian annexation of Crimea; long-lasting tensions over Russian support for pro-independence fighters in eastern Ukraine; Russian anger over the promotion of Color Revolutions in its backyard, especially Georgia; and Russian weapons that were allegedly involved in the shooting down of a Malaysian Airlines jetliner that had killed all onboard; Russo-EU ties are strained. Russo-US ties are also strained for the same reason but the US under the Trump administration is keen to reach rapprochement with the Russians. In fact, in his meeting with NATO allies, President Trump pushed hard for the revival of the G-8 (the G-7 plus Russia). President Trump is trying very hard to reboot American relations with the Russians, something of great significance between the world’s top two nuclear powers armed with enough ICBMs to destroy the world many times over. President Trump’s overtures are resisted by many: his Democrat colleagues, European leaders and his own intelligence services. This is a complicated situation.

        We post our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, on the investor relations section of our public website (www.rapharma.com), free of charge, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, you can read our SEC filings over the Internet at the SEC’s website at https://www.sec.gov/. The contents of these websites are not incorporated into this Annual Report on Form 10-K. Further, our references to the URLs for these websites are intended to be inactive textual references only.

Totally agree, her work is brilliant. I guess Blackburn prefers science to stay theoretical and never actually benefit anyone.